Graft Versus Host Disease Treatment Market Research and Forecast by 2032

Posted by Ganesh Shinde on April 17th, 2023

By 2032, the global Graft Versus Host Disease (GvHD) treatment market is expected to hit US$ 5,655.37 million, with a compounded annual growth rate of 8.3%. The popularity of corticosteroids and combination therapy for GvHD in hematopoietic cell transplant (HCT) patients has contributed to the market's growth, which is projected to be worth ,547.86 million in 2022, having grown at a rate of 7.8% between 2016 and 2021.

While recent advancements in overall survival and acute GVHD severity levels have benefited allogeneic HCT patients, several challenges remain. Jakafi and Rezurock, two newly approved medications, may be more effective than older drugs in preventing and treating chronic GVHD.

In December 2021, the US Food and Drug Administration approved Orencia (abatacept) for the treatment of GVHD in both adult and pediatric patients. Orencia, which is also used to prevent autoimmune disorders, targets T-cells, a critical component of acute GVHD, by binding to and modulating one of the main costimulation signals these cells send. This prevents T-cells from fully activating and causing acute GVHD. Doctors are currently exploring new approaches to prevent GVHD in the future.

Moreover, Orencia's approval will expand access to stem cell transplants for a broader range of cancer patients and people with blood disorders, particularly those from diverse ethnic backgrounds. Immunosuppression, as well as regenerative or tissue-repairing agents, may be added to the market in the future to improve treatment response.

Competition Analysis

Key players in the global graft versus host disease (GvHD) treatment market include Sanofi, Equillium, Inc., Novartis AG, Neovii Biotech GmbH, Merck & Co., Astellas Pharma Inc.,Soligenix, Inc., Mesoblast Ltd, Pfizer, Takeda Pharmaceutical, Abbott, and others.

Get More Details@ https://www.futuremarketinsights.com/reports/graft-versus-host-disease-gvhd-treatment-market

Key Segments Profiled In The Global Graft Versus Host Disease (Gvhd) Treatment Market

Graft Versus Host Disease (GvHD) Treatment Market by Product:

• Monoclonal antibodies Graft Versus Host Disease (GvHD) Treatment
• mTOR inhibitors Graft Versus Host Disease (GvHD) Treatment
• Tyrosine kinase inhibitors Graft Versus Host Disease (GvHD) Treatment
• Thalidomide Graft Versus Host Disease (GvHD) Treatment
• Etanercept Graft Versus Host Disease (GvHD) Treatment

Graft Versus Host Disease (GvHD) Treatment Market by Disease:

• Acute Graft Versus Host Disease (a(GvHD)
• Chronic Graft Versus Host Disease (c(GvHD)